Skip to main content

Articles

Page 3 of 10

  1. The identification of biomarkers to select patients with metastatic renal cell carcinoma (mRCC) most likely to respond to combination immunotherapy (IO) is needed. We sought to investigate an association of th...

    Authors: Matthew D. Tucker, Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, Kathryn E. Beckermann, Nancy B. Davis, Renee McAlister, Kerry Schaffer, Andrew J. Armstrong, Michael R. Harrison, Daniel J. George, W. Kimryn Rathmell, Brian I. Rini…
    Citation: Biomarker Research 2021 9:80
  2. Immune checkpoint inhibitors (ICIs) have heralded the advent of a new era in oncology by holding the promise of prolonged survival in severe and otherwise treatment-refractory advanced cancers. However, the re...

    Authors: Xiaoyan Liu, Yuequan Shi, Dongming Zhang, Qing Zhou, Jia Liu, Minjiang Chen, Yan Xu, Jing Zhao, Wei Zhong and Mengzhao Wang
    Citation: Biomarker Research 2021 9:79
  3. The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of ...

    Authors: Takahiro Einama, Yoji Yamagishi, Yasuhiro Takihata, Takafumi Suzuki, Tamio Yamasaki, Yuichi Hirose, Kazuki Kobayashi, Naoto Yonamine, Ibuki Fujinuma, Takazumi Tsunenari, Makiko Koga, Yusuke Ishibashi, Ken Nagata, Takehiro Shiraishi, Akiko Nakazawa, Toshimitsu Iwasaki…
    Citation: Biomarker Research 2021 9:78
  4. Myeloid-derived suppressor cells (MDSC) are a group of immature cells that produced by emergency myelopoiesis. Emerging evidences have identified the vital role of MDSC in cancer microenvironment, in which MDS...

    Authors: Zhaonian Hao, Ruyuan Li, Yuanyuan Wang, Shuangying Li, Zhenya Hong and Zhiqiang Han
    Citation: Biomarker Research 2021 9:77

    The Correction to this article has been published in Biomarker Research 2022 10:7

  5. The ten-eleven translocation 1 (TET1) protein is a 5-methylcytosine hydroxylase that belongs to the TET protein family of human α-ketoglutarate oxygenases. TET1 recognizes and binds to regions of high genomic ...

    Authors: Wenzheng Liu, Guanhua Wu, Fei Xiong and Yongjun Chen
    Citation: Biomarker Research 2021 9:76
  6. Multiple myeloma (MM) is a treatable plasma cell cancer with no cure. Clinical evidence shows that the status of minimal residual disease (MRD) after treatment is an independent prognostic factor of MM. MRD in...

    Authors: Hong Ding, Juan Xu, Zhimei Lin, Jingcao Huang, Fangfang Wang, Yan Yang, Yushan Cui, Hongmei Luo, Yuhan Gao, Xinyu Zhai, Weicui Pang, Li Zhang and Yuhuan Zheng
    Citation: Biomarker Research 2021 9:75
  7. Earlier studies have shown that lymphomatous effusions in patients with diffuse large B-cell lymphoma (DLBCL) are associated with a very poor prognosis, even worse than for non-effusion-associated patients wit...

    Authors: Sina Abdollahi, Seyedeh Zahra Dehghanian, Liang-Yi Hung, Shiang-Jie Yang, Dao-Peng Chen, L. Jeffrey Medeiros, Jung-Hsien Chiang and Kung-Chao Chang
    Citation: Biomarker Research 2021 9:74
  8. The role of PLAC8 in tumorigenesis has been gradually elucidated with the development of research. Although there are common molecular mechanisms that enforce cell growth, the impact of PLAC8 is varied and can, i...

    Authors: Misha Mao, Yifan Cheng, Jingjing Yang, Yongxia Chen, Ling Xu, Xun Zhang, Zhaoqing Li, Cong Chen, Siwei Ju, Jichun Zhou and Linbo Wang
    Citation: Biomarker Research 2021 9:73
  9. Tumor-associated macrophages (TAMs), at the core of immunosuppressive cells and cytokines networks, play a crucial role in tumor immune evasion. Increasing evidences suggest that potential mechanisms of macrop...

    Authors: Yingqi Qiu, Tong Chen, Rong Hu, Ruiyi Zhu, Chujun Li, Yingchen Ruan, Xiaoling Xie and Yuhua Li
    Citation: Biomarker Research 2021 9:72
  10. Biological therapy is considered an alternative treatment capable of eliciting the same effects on tumors as surgery, radiotherapy, and chemotherapy. As a major player in biological therapy, oncolytic viruses ...

    Authors: Shengye Jin, Qin Wang, Hao Wu, Da Pang and Shouping Xu
    Citation: Biomarker Research 2021 9:71
  11. The use of blood biomarkers after mild traumatic brain injury (mTBI) has been widely studied. We have identified eight unresolved issues related to the use of five commonly investigated blood biomarkers: neuro...

    Authors: Daniel B. Hier, Tayo Obafemi-Ajayi, Matthew S. Thimgan, Gayla R. Olbricht, Sima Azizi, Blaine Allen, Bassam A. Hadi and Donald C. Wunsch II
    Citation: Biomarker Research 2021 9:70
  12. Lack of biomarkers and in vitro models has contributed to inadequate understanding of the mechanisms underlying the inferior clinical response to immune checkpoint inhibitors (ICIs) in patients with oncogene-d...

    Authors: Weijie Ma, Jie Zeng, Shuai Chen, Yue Lyu, Kyra A. Toomey, Chinh T. Phan, Ken Y. Yoneda and Tianhong Li
    Citation: Biomarker Research 2021 9:69
  13. Wnt signaling was initially recognized to be vital for tissue development and homeostasis maintenance. Further studies revealed that this pathway is also important for tumorigenesis and progression. Abnormal e...

    Authors: Zhuo Wang, Tingting Zhao, Shihui Zhang, Junkai Wang, Yunyun Chen, Hongzhou Zhao, Yaxin Yang, Songlin Shi, Qiang Chen and Kuancan Liu
    Citation: Biomarker Research 2021 9:68
  14. Extracellular vesicles are membrane vesicles that are released into the extracellular environment and accumulate in the circulation in vascular disease. We aimed to quantify circulating extracellular vesicles ...

    Authors: Akram Abolbaghaei, Marc-André Langlois, Helen R Murphy, Denice S. Feig and Dylan Burger
    Citation: Biomarker Research 2021 9:67
  15. Deubiquitinases (DUBs) are enzymes that control the stability, interactions or localization of most cellular proteins by removing their ubiquitin modification. In recent years, some DUBs, such as USP7, USP9X a...

    Authors: Hu Lei, Jiaqi Wang, Jiacheng Hu, Qian Zhu and Yingli Wu
    Citation: Biomarker Research 2021 9:66
  16. MicroRNAs may be important regulators of risk for type 2 diabetes. The purpose of this longitudinal observational study was to assess whether circulating microRNAs predicted improvements in fasting blood gluco...

    Authors: Elena Flowers, Isabel Elaine Allen, Alka M. Kanaya and Bradley E. Aouizerat
    Citation: Biomarker Research 2021 9:65
  17. Cell therapy has evolved rapidly in the past several years with more than 250 clinical trials ongoing around the world. While more indications of cellular therapy with chimeric antigen receptor – engineered T ...

    Authors: Hongtao Liu, Chongxian Pan, Wenru Song, Delong Liu, Zihai Li and Lei Zheng
    Citation: Biomarker Research 2021 9:62
  18. Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have recently been characterized as attractive targets for cancer immunotherapy. Owing to the development of next-generatio...

    Authors: Xuan Zhao, Xiaoxin Pan, Yi Wang and Yi Zhang
    Citation: Biomarker Research 2021 9:61
  19. Tumor angiogenesis induces local hypoxia and recruits immunosuppressive cells, whereas hypoxia subsequently promotes tumor angiogenesis. Immunotherapy efficacy depends on the accumulation and activity of tumor...

    Authors: Wuzhen Chen, Lesang Shen, Jingxin Jiang, Leyi Zhang, Zhigang Zhang, Jun Pan, Chao Ni and Zhigang Chen
    Citation: Biomarker Research 2021 9:59
  20. In Western countries, ovarian cancer (OC) still represents the leading cause of gynecological cancer-related deaths, despite the remarkable gains in therapeutical options. Novel biomarkers of early diagnosis, ...

    Authors: E. Krasniqi, A. Sacconi, D. Marinelli, L. Pizzuti, M. Mazzotta, D. Sergi, E. Capomolla, S. Donzelli, M. Carosi, A. Bagnato, T. Gamucci, S. Tomao, C. Natoli, P. Marchetti, A. Grassadonia, N. Tinari…
    Citation: Biomarker Research 2021 9:57
  21. Contemporary to the rapidly evolving landscape of cancer immunotherapy is the equally changing understanding of immune tumor microenvironments (TMEs) which is crucial to the success of these therapies. Their r...

    Authors: Sarabjot Pabla, R. J. Seager, Erik Van Roey, Shuang Gao, Carrie Hoefer, Mary K. Nesline, Paul DePietro, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Margot Schoenborn, Shengle Zhang, Roger Klein, Sean T. Glenn…
    Citation: Biomarker Research 2021 9:56
  22. Every year around the world, more than 2 million women are diagnosed with breast cancer and genital tract cancers. However, there are rare studies comprehensively describing the global and regional trends of i...

    Authors: Ming Yi, Tianye Li, Mengke Niu, Suxia Luo, Qian Chu and Kongming Wu
    Citation: Biomarker Research 2021 9:55
  23. Long non-coding RNAs (lncRNAs) represent a diverse class of RNAs involved in the regulation of various physiological and pathological cellular processes, including transcription, intracellular trafficking, and...

    Authors: Francesca Maria Orlandella, Giovanni Smaldone, Giuliana Salvatore, Luigi Vitagliano, Alessandra Cianflone, Rosanna Parasole, Giuliana Beneduce, Giuseppe Menna, Marco Salvatore and Peppino Mirabelli
    Citation: Biomarker Research 2021 9:54
  24. Myelodysplastic syndrome with myelofibrosis (MDS-MF) has been associated with an inferior prognosis compared with MDS without MF. However, MDS-MF is not listed independently as a subtype of MDS, and its clinic...

    Authors: Minghua Hong, Junqing Wu, Lifeng Ma, Xiaoping Han, Ting Lu, Zhaoming Wang, Jing Zhao, Lizhen Liu, Huarui Fu, Weijia Huang, Weiyan Zheng, Jingsong He, Guoqing Wei, Huanping Wang, Zhimei Chen, He Huang…
    Citation: Biomarker Research 2021 9:53
  25. After decades during which the treatment of acute myeloblastic leukemia was limited to variations around a skeleton of cytarabine/anthracycline, targeted therapies appeared. These therapies, first based on mon...

    Authors: Lamia Madaci, Julien Colle, Geoffroy Venton, Laure Farnault, Béatrice Loriod and Régis Costello
    Citation: Biomarker Research 2021 9:50
  26. Tumor immunotherapy has attracted more and more attention nowadays, and multiple clinical trials have confirmed its effect in a variety of solid tumors. Immune checkpoint inhibitors (ICIs), cancer vaccines, ad...

    Authors: Wenyu Cao, Xinyue Ma, Jean Victoria Fischer, Chenggong Sun, Beihua Kong and Qing Zhang
    Citation: Biomarker Research 2021 9:49
  27. SMAD1, a central mediator in TGF-β signaling, is involved in a broad range of biological activities including cell growth, apoptosis, development and immune response, and is implicated in diverse type of malig...

    Authors: Jian Wu, Min Zhang, Omar Faruq, Eldad Zacksenhaus, Wenming Chen, Aijun Liu and Hong Chang
    Citation: Biomarker Research 2021 9:48
  28. Metastasis suggests a poor prognosis for cancer patients, and treatment strategies for metastatic cancer are still very limited. Numerous studies have shown that cancer-associated fibroblasts (CAFs), a large c...

    Authors: Zimu Wang, Jiaxin Liu, Hairong Huang, Mingxiang Ye, Xinying Li, Ranpu Wu, Hongbing Liu and Yong Song
    Citation: Biomarker Research 2021 9:47
  29. Myelodysplastic syndrome (MDS) is an aggressive and genetically heterogeneous disease with poor prognosis. Cellular immune disorder is a common characteristic of this disease and is thought to be related to cl...

    Authors: Xin Huang, Cunte Chen, Mengjun Zhong, Suxia Geng, Yujie Zhao, Minming Li, Chenxin Deng, Lingji Zeng, Ping Wu, Zesheng Lu, Jianyu Weng, Xin Du and Yangqiu Li
    Citation: Biomarker Research 2021 9:46
  30. Although some studies have demonstrated that lncRNAs are dysregulated in hematopoietic malignancies and may regulate the progression of leukemia, the detailed mechanism underlying tumorigenesis is still unclea...

    Authors: Xuanmei Huang, Libin Huang, Qing Xie, Ling Zhang, Shaohui Huang, Mingye Hong, Jiangbin Li, Zunnan Huang and Hua Zhang
    Citation: Biomarker Research 2021 9:45
  31. The E-Cadherin gene (CDH1, Cadherin 1), located at 16q22.1 encodes for a calcium-dependent membranous glycoprotein with an important role in cellular adhesion and polarity maintenance.

    Authors: Eike Burandt, Felix Lübbersmeyer, Natalia Gorbokon, Franziska Büscheck, Andreas M. Luebke, Anne Menz, Martina Kluth, Claudia Hube-Magg, Andrea Hinsch, Doris Höflmayer, Sören Weidemann, Christoph Fraune, Katharina Möller, Frank Jacobsen, Patrick Lebok, Till Sebastian Clauditz…
    Citation: Biomarker Research 2021 9:44
  32. Oral squamous cell carcinoma (OSCC) is a capricious cancer with poor survival rates, even for early-stage patients. There is a pressing need to develop more precise risk assessment methods to appropriately tai...

    Authors: Chi T. Viet, Gary Yu, Kesava Asam, Carissa M. Thomas, Angela J. Yoon, Yan Chen Wongworawat, Mina Haghighiabyaneh, Courtney A. Kilkuts, Caitlyn M. McGue, Marcus A. Couey, Nicholas F. Callahan, Coleen Doan, Paul C. Walker, Khanh Nguyen, Stephanie C. Kidd, Steve C. Lee…
    Citation: Biomarker Research 2021 9:42
  33. It has been suggested that the heterogeneity of TAAs in lung cancer may affect the therapeutic response and disease progression. Up to now, several tumor-associated antigen (TAA)-based cancer vaccines have bee...

    Authors: Fang Lv, Xueying Wu, Jin Song, Pan Wang, Shucheng Ren, Wei Guo, Qi Xue, Henghui Zhang and Jun Zhao
    Citation: Biomarker Research 2021 9:41
  34. N6-methyladenosine (m6A) modification is the most prevalent internal mRNA modification and is involved in many biological processes in eukaryotes. Accumulating evidence has demonstrated that m6A may play eithe...

    Authors: Fangchao Zheng, Feng Du, Jiuda Zhao, Xue Wang, Yiran Si, Peng Jin, Haili Qian, Binghe Xu and Peng Yuan
    Citation: Biomarker Research 2021 9:39
  35. T cell-based immunotherapies have revolutionized treatment paradigms in various cancers, however, limited response rates secondary to lack of significant T-cell infiltration in the tumor site remain a major pr...

    Authors: Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng and Jinming Yu
    Citation: Biomarker Research 2021 9:38
  36. Mechanisms driving the progression of chronic lymphocytic leukemia (CLL) from its early stages are not fully understood. The acquisition of molecular changes at the time of progression has been observed in a s...

    Authors: Isabel Jiménez, Bárbara Tazón-Vega, Pau Abrisqueta, Juan C. Nieto, Sabela Bobillo, Carles Palacio-García, Júlia Carabia, Rafael Valdés-Mas, Magdalena Munuera, Lluís Puigdefàbregas, Genís Parra, Anna Esteve-Codina, Clara Franco-Jarava, Gloria Iacoboni, María José Terol, José Antonio García-Marco…
    Citation: Biomarker Research 2021 9:37
  37. Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane re...

    Authors: Jayna J Mistry, Charlotte Hellmich, Amelia Lambert, Jamie A Moore, Aisha Jibril, Angela Collins, Kristian M Bowles and Stuart A Rushworth
    Citation: Biomarker Research 2021 9:35
  38. The myristoylated alanine-rich C-kinase substrate (MARCKS) protein has been at the crossroads of multiple signaling pathways that govern several critical operations in normal and malignant cellular physiology....

    Authors: Deepak Narayanan Iyer, Omar Faruq, Lun Zhang, Nasrin Rastgoo, Aijun Liu and Hong Chang
    Citation: Biomarker Research 2021 9:34
  39. Reversion of tumor to a normal differentiated cell once considered a dream is now at the brink of becoming a reality. Different layers of molecules/events such as microRNAs, transcription factors, alternative ...

    Authors: Avantika Tripathi, Anjali Kashyap, Greesham Tripathi, Joni Yadav, Rakhi Bibban, Nikita Aggarwal, Kulbhushan Thakur, Arun Chhokar, Mohit Jadli, Ashok Kumar Sah, Yeshvandra Verma, Hatem Zayed, Amjad Husain, Alok Chandra Bharti and Manoj Kumar Kashyap
    Citation: Biomarker Research 2021 9:31

Annual Journal Metrics